
What drinking alcohol when you're on statins really does to your body
With more than 10 million people in England now eligible for statins, the cholesterol lowering drugs (which are prescribed to reduce risk of cardiovascular diseases and prevent further damage for people who have already had a heart attack) it's inevitable that some will want to keep enjoying the odd drink while taking their medications (although perhaps not simultaneously).
This is particularly true after the National Institute for Health and Care Excellence (Nice) watchdog adjusted their guidelines in 2023 to lower the age of eligibility for statins down to 25, meaning that younger patients – especially those with underlying genetic risk factors – deemed to be at a higher short-term risk of heart problems can now be offered the drugs.
But can statins and alcohol really be combined? Are some worse than others? Or are they quite simply, a marriage made in hell?
How does drinking alcohol affect the body when on statins?
Dr Raul Santos, a Brazilian cardiologist who serves as editor-in-chief for the World Heart Federation's Global Heart Journal, is keen to emphasise that statins are, overall, extremely safe medications. 'They've been used by millions of people for decades to reduce cholesterol, and prevent myocardial infarctions [the medical term for heart attacks] and stroke,' says Dr Santos.
However, people can sometimes run into issues when combining them with alcohol, because the way in which statins lower LDL or 'bad' cholesterol is through acting on a series of biological pathways in the liver.
In particular, statins inhibit an enzyme which actively decreases the continuing production of cholesterol, as well as enhancing the uptake and breakdown of existing LDL cholesterol in the blood.
How does this affect our livers?
The problem, as pointed out by Dr Oliver Guttmann, a consultant cardiologist at St Bartholomew's Hospital in London, is that alcohol also acts on various enzymes in the liver. 'They're both going down the same waterway, so to speak,' says Dr Guttmann. 'So the main concern is that there's going to be some kind of congestion.'
With statins altering the liver's natural function, and alcohol needing to be metabolised, Dr Guttmann says that having too much booze in your system risks impeding the liver's ability to carry out its vital functions such as breaking down and detoxifying toxins.
'When statins and alcohol are combined at a high level, there's an increased risk of liver inflammation or damage,' he adds.
It's also not great news for those who are taking statins for the long-term.
Some research indicates that excessive alcohol might impair the long-term health benefits of taking statins. As well as reducing LDL cholesterol, these drugs also improve cardiovascular health by lowering the amounts of another subtype of fat in the blood called triglycerides. But because alcohol is surprisingly calorific, consuming too much of it can send triglycerides straight back up again.
'The whole point of taking statins is to lower cholesterol and triglycerides and decrease the furring up the blood vessels in the body, especially the coronary arteries around the heart, and in the neck leading up to the brain,' explains Dr Guttmann. 'But alcohol, if not taken in moderation, can actively increase the formation of plaques and high concentrations of it can cause narrowing of blood vessels. So through too much alcohol, you're driving the things you're trying to prevent.'
What are the risks of taking statins and drinking?
According to Guttmann, people taking statins with underlying liver problems such as fatty liver disease or hepatitis, are more likely to be at risk of developing issues through consuming too much alcohol.
Certain statins may also carry a higher risk of adverse effects. Dr Roy Jogiya, the chief medical adviser at Heart Research UK and a consultant cardiologist at Kingston and St Thomas Hospital NHS Foundation Trust, says side effects are more likely with simvastatin and atorvastatin in particular, such as fatigue or gastrointestinal issues.
'These statins are processed by a liver enzyme (called CYP3A4) which can also be affected by alcohol,' says Dr Jogiya. 'This means there may be a slightly higher risk of liver-related side effects in the context of heavy drinking. That said, for most people drinking in moderation, the difference is unlikely to be clinically significant, but we take these factors into account when prescribing.'
Does alcohol worsen statin side effects?
The risk of worsening muscle aches and pains has sometimes been described as one of the main factors which puts people off taking statins, and according to cardiologists, there is a chance that alcohol may exacerbate this.
One of the reasons for this is that excess alcohol can not only drive muscle inflammation but disable certain liver enzymes which break down and clear statins from the body, meaning that the liver is being exposed to higher levels of the drugs. 'It's as if you're taking a higher dose of the statin,' says Dr Guttmann.
Dr Santos agrees that this is a possibility. 'Alcohol can cause or exacerbate muscle pains and digestive issues in people taking statins, and one should be aware of that,' he warns. 'The right thing to do is stop or reduce drinking, rather than stopping statins or other cholesterol-lowering medications.'
At the same time, Dr Santos points out that while muscle aches are typically attributed to statins, clinical trials suggest that pains directly caused by a statin are quite rare, only occurring in 1-3 per cent of users.
'Muscle aches are sometimes reported by people on statins, but in many cases, they're caused by other factors, not the statin itself,' says Dr Jogiya. 'That said, alcohol can contribute to dehydration and may affect muscle function, which could make symptoms more noticeable.'
One of the most serious statin concerns is a very rare side effect called rhabdomyolysis, or the complete breakdown of muscle cells, which occurs in 0.01 per cent of users. Dr Guttmann says that too much alcohol could also exacerbate this effect, but the overall chances of this happening are still very unlikely.
Are there newer statins which have different affects with alcohol?
Dr Guttmann says that if anyone is particularly concerned about statin-alcohol interactions, he would recommend taking either newer forms of the drugs such as pravastatin or rosuvastatin. 'While they're metabolised by the liver as well, it's not by the same enzymes, and therefore, there's a lower risk of liver-related effects,' he explains.
How much booze is too much?
So how much alcohol should you stick to? Dr Santos suggests that all statin users should aim to stay within the guidelines of seven units per week for women and 14 units for men, while Dr Guttmann says that drinking advice should take into account whether the patient has any other underlying liver conditions.
'It depends on other conditions: does the patient have fatty liver, or cirrhosis which is a very significant liver problem?' he says. 'Do they have hepatitis or any underlying muscle or kidney problems? Do they take any other medications, as lots of drugs also work on the liver, and sometimes a combination of things can be quite toxic. So all of this needs to be discussed with their doctor.'
But overall, if a patient really wants to have the option to continue drinking alongside statins, Dr Guttmann says that the equivalent of one standard glass of wine per day is what he suggests as a general rule.
'This is usually what I would recommend,' he says. 'And you shouldn't drink every day, maybe have some gaps, but that should be OK.'
Dr Jogiya says: 'In short – yes, but with care. Moderate alcohol consumption is unlikely to cause issues for most people taking statins, but it's important to look at the bigger picture.
'Statins are prescribed to protect long-term heart health, and drinking habits should ideally align with that goal. Occasional, moderate drinking, particularly when enjoyed with food and within recommended weekly limits, can usually be managed safely. I'd always recommend discussing it with a GP or pharmacist, especially if there are any concerns about side effects or liver function.'
Dr Guttmann adds: 'Generally, if you have a little bit of alcohol, no more than a glass of wine a day, it's generally safe. I don't really come across people who have been advised not to have any alcohol at all with statins. But the bottom line is that moderation is really important. Heavy or chronic drinking will significantly increase your risk of statin-related problems.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Scottish Sun
a day ago
- Scottish Sun
Thousands of men given ‘unnecessary' cancer treatment every year due to ‘wild west' guidelines
A leading cancer charity says "enough is enough" as it calls for Nice to update its advice 'HARMFUL' Thousands of men given 'unnecessary' cancer treatment every year due to 'wild west' guidelines Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) UP to 5,000 men every could avoid unnecessary cancer treatment if "outdated" guidelines reflected latest evidence, a charity has urged. Overtreatment can lead to side effects such as erectile dysfunction or incontinence, it warned. Sign up for Scottish Sun newsletter Sign up 1 For men whose prostate cancer is unlikely to progress, experts suggest close monitoring is the "best" option - but advice on this hasn't been updated since 2021 Credit: Getty Prostate cancer is a leading cause of cancer deaths in males in the UK, with around 55,000 new cases diagnosed every year. However, in some cases, the cancer is slow-growing and unlikely to ever cause the patient harm. For men whose cancer is unlikely to progress, experts suggest close monitoring is the "best" option. However, out-of-date guidance from the National Institute of Health and Care Excellence (Nice) on how this is implemented has created a "wild west". Close monitoring involves blood tests and scans, known as active surveillance. Nice guidance on active surveillance is designed to advise specialists on how to implement monitoring and which men should be monitored. However, it hasn't been updated since 2021, according to Prostate Cancer UK. A Freedom of information (FOI) request analysis by the charity found around one in four (24 per cent) of hospitals rely on Nice guidance alone to implement active surveillance. It also found 35 hospitals have created their own guidelines, which Prostate Cancer UK warned can lead to inconsistency and confusion among medics. The charity is now repeating its call for Nice to update its guidance on active surveillance, claiming it could help up to 5,000 men a year avoid overtreatment. I thought I was drinking too much tea - but it was actually a deadly condition It also claims the outdated guidance is hindering a screening programme for prostate cancer. Amy Rylance, assistant director of health improvement at Prostate Cancer UK, said: "To reduce the harm caused by prostate cancer and build the foundations for a screening programme, we need to both save lives and prevent unnecessary treatment but official guidelines still haven't caught up with the clinical evidence. "Concerns about overtreatment are a major reason the UK does not routinely screen for prostate cancer, despite it being the most common cancer in England. "Acting on latest research that shows more men can safely opt for monitoring instead of treatment will reduce overtreatment and the harm it causes men. "We asked Nice to update their active surveillance guidance two years ago, but our request was rejected. Now we have evidence this is potentially affecting thousands of men. Enough is enough." Current testing for prostate cancer The NHS uses a prostate-specific antigen (PSA) blood test to check for prostate conditions, including prostate cancer or an enlarged prostate. Routine PSA testing is not currently offered on the NHS, but patients may be offered a PSA test if a GP suspects they have prostate cancer, while men over 50 can request a test from their GP even if they do not have symptoms. But there have been calls to roll the test out across the health service, although some argue widespread use could identify cases which may not have caused problems or needed treatment. Vincent Gnanapragasam, a professor of urology at the University of Cambridge, said: "Active surveillance is the best treatment option for men whose cancer is unlikely to progress or cause them problems in their lifetime. "But Nice's outdated guidelines have created a deeply concerning wild west on how surveillance is implemented by different healthcare teams. What is prostate cancer? Prostate cancer affects a small, walnut shaped gland that sits underneath the bladder and surrounds the urethra - the tube carrying pee outside the body. It usually grows bigger as you get older. The prostate's main job is to help make semen – the fluid that carries sperm. Most men with early prostate cancer don't have any signs or symptoms - that's why it's important to know about your risk. Possible symptoms include: Difficulty starting to urinate or emptying your bladder A weak flow when you urinate A feeling that your bladder hasn't emptied properly Dribbling urine after you finish urinating Needing to urinate more often than usual, especially at night A sudden need to urinate – you may sometimes leak urine before you get to the toilet If you do notice changes in the way you urinate, this is more likely to be a sign of an enlarged prostate, which is very common and non-cancerous. But it's still a good idea to get it checked out. In the UK, about one in eight men will be diagnosed with prostate cancer in their lifetime. Some factors may mean you're more likely to get it. This includes: Getting older – it mainly affects men aged 50 or over Having a family history of prostate cancer Being Black If you have any of these risk factors or if you have any symptoms, speak to your GP. They can talk to you about your risk, and about the tests that are used to diagnose prostate cancer. Source: Prostate Cancer UK "This inconsistency is resulting in a lack of confidence from patients in surveillance, who may instead opt to have treatment they may not have ever needed, risking harmful side effects. "Programmes for active surveillance that are standardised and individualised to a man's risk factors have been tested and proven to work." The UK's National Screening Committee is currently assessing whether a national screening programme for prostate cancer should be rolled out. A Nice spokesperson said: "We are committed to ensuring our guidelines continue to reflect the best available evidence and give patients the best possible outcomes. "They are developed by an independent committee, including NHS clinical experts, and are kept under review to ensure they remain current. "We are updating our prostate cancer guidelines, including a review of the recommendations around active surveillance, and will be assessing whether our suspected cancer guideline recommendations around age-related thresholds for PSA tests for prostate cancer for onwards referral from primary care require updating."


The Sun
a day ago
- The Sun
Thousands of men given ‘unnecessary' cancer treatment every year due to ‘wild west' guidelines
UP to 5,000 men every could avoid unnecessary cancer treatment if "outdated" guidelines reflected latest evidence, a charity has urged. Overtreatment can lead to side effects such as erectile dysfunction or incontinence, it warned. 1 Prostate cancer is a leading cause of cancer deaths in males in the UK, with around 55,000 new cases diagnosed every year. However, in some cases, the cancer is slow-growing and unlikely to ever cause the patient harm. For men whose cancer is unlikely to progress, experts suggest close monitoring is the "best" option. However, out-of-date guidance from the National Institute of Health and Care Excellence (Nice) on how this is implemented has created a "wild west". Close monitoring involves blood tests and scans, known as active surveillance. Nice guidance on active surveillance is designed to advise specialists on how to implement monitoring and which men should be monitored. However, it hasn't been updated since 2021, according to Prostate Cancer UK. A Freedom of information (FOI) request analysis by the charity found around one in four (24 per cent) of hospitals rely on Nice guidance alone to implement active surveillance. It also found 35 hospitals have created their own guidelines, which Prostate Cancer UK warned can lead to inconsistency and confusion among medics. The charity is now repeating its call for Nice to update its guidance on active surveillance, claiming it could help up to 5,000 men a year avoid overtreatment. I thought I was drinking too much tea - but it was actually a deadly condition It also claims the outdated guidance is hindering a screening programme for prostate cancer. Amy Rylance, assistant director of health improvement at Prostate Cancer UK, said: "To reduce the harm caused by prostate cancer and build the foundations for a screening programme, we need to both save lives and prevent unnecessary treatment but official guidelines still haven't caught up with the clinical evidence. "Concerns about overtreatment are a major reason the UK does not routinely screen for prostate cancer, despite it being the most common cancer in England. "Acting on latest research that shows more men can safely opt for monitoring instead of treatment will reduce overtreatment and the harm it causes men. "We asked Nice to update their active surveillance guidance two years ago, but our request was rejected. Now we have evidence this is potentially affecting thousands of men. Enough is enough." Current testing for prostate cancer The NHS uses a prostate-specific antigen (PSA) blood test to check for prostate conditions, including prostate cancer or an enlarged prostate. Routine PSA testing is not currently offered on the NHS, but patients may be offered a PSA test if a GP suspects they have prostate cancer, while men over 50 can request a test from their GP even if they do not have symptoms. But there have been calls to roll the test out across the health service, although some argue widespread use could identify cases which may not have caused problems or needed treatment. Vincent Gnanapragasam, a professor of urology at the University of Cambridge, said: "Active surveillance is the best treatment option for men whose cancer is unlikely to progress or cause them problems in their lifetime. "But Nice's outdated guidelines have created a deeply concerning wild west on how surveillance is implemented by different healthcare teams. What is prostate cancer? Prostate cancer affects a small, walnut shaped gland that sits underneath the bladder and surrounds the urethra - the tube carrying pee outside the body. It usually grows bigger as you get older. The prostate's main job is to help make semen – the fluid that carries sperm. Most men with early prostate cancer don't have any signs or symptoms - that's why it's important to know about your risk. Possible symptoms include: Difficulty starting to urinate or emptying your bladder A weak flow when you urinate A feeling that your bladder hasn't emptied properly Dribbling urine after you finish urinating Needing to urinate more often than usual, especially at night A sudden need to urinate – you may sometimes leak urine before you get to the toilet If you do notice changes in the way you urinate, this is more likely to be a sign of an enlarged prostate, which is very common and non-cancerous. But it's still a good idea to get it checked out. In the UK, about one in eight men will be diagnosed with prostate cancer in their lifetime. Some factors may mean you're more likely to get it. This includes: Getting older – it mainly affects men aged 50 or over Having a family history of prostate cancer Being Black If you have any of these risk factors or if you have any symptoms, speak to your GP. They can talk to you about your risk, and about the tests that are used to diagnose prostate cancer. Source: Prostate Cancer UK "This inconsistency is resulting in a lack of confidence from patients in surveillance, who may instead opt to have treatment they may not have ever needed, risking harmful side effects. "Programmes for active surveillance that are standardised and individualised to a man's risk factors have been tested and proven to work." The UK's National Screening Committee is currently assessing whether a national screening programme for prostate cancer should be rolled out. A Nice spokesperson said: "We are committed to ensuring our guidelines continue to reflect the best available evidence and give patients the best possible outcomes. "They are developed by an independent committee, including NHS clinical experts, and are kept under review to ensure they remain current. "We are updating our prostate cancer guidelines, including a review of the recommendations around active surveillance, and will be assessing whether our suspected cancer guideline recommendations around age-related thresholds for PSA tests for prostate cancer for onwards referral from primary care require updating." One in eight men will get prostate cancer The risk of developing prostate cancer depends on many factors, here are some of the facts about the disease and how many men it affects. One in eight men will get prostate cancer in their lifetime It is the fourth most common cancer worldwide, and the most common in men There are 55,000 new cases every year in the UK, and 1.4million globally Around 12,000 people lose their lives to prostate cancer annually in the UK and almost 400,000 around the world Prostate cancer accounts for 28 per cent of all new cancer cases in men in the UK, and 14 per cent of all new cancer cases in men and women combined Prostate cancer survival has tripled in the last 50 years in the UK More than three-quarters (78 per cent) of patients survive for 10 or more years About 490,000 men are living with and after prostate cancer in the UK It is most common in men aged 75 to 79 Since the early 1990s, cases have increased by 53 per cent in the UK Mortality rates are up 16 per cent since the early 1970s in the UK Incidence rates are projected to rise by 15 per cent in the UK between 2023 to 2025 and 2038 to 2040 Mortality rates are expected to fall five per cent in the UK over the same years


BBC News
a day ago
- BBC News
Men being over-treated for prostate cancer, says charity
The NHS is over-treating men for prostate cancer, a charity says, with around 5,000 a year undergoing treatment for cancers unlikely ever to cause one in four prostate cancers are so slow growing that men can opt for regular monitoring rather than treatment, such as surgery and radiotherapy, which can cause side-effects such as incontinence and erectile dysfunctionOf the 56,000 diagnosed in the UK each year, around 6,500 men opt for this, but an analysis by Prostate Cancer UK said another 5,000 could charity said outdated guidelines were to blame. The National Institute for Health and Care Excellence (NICE), which produces them, said it was reviewing its advice. NICE recommends that monitoring, using blood tests and scans, should be offered to the lowest risk cases, where nine in 10 will have no signs of cancer spreading within five research has suggested this could be extended to the next lowest risk group where eight in 10 men will have no signs of cancer spreading. Evidence gathered by Prostate Cancer UK suggests many hospitals have started offering monitoring to this wider group of patients, but a quarter have to the charity's analysis:in some hospitals in England, 24% of patients who could be monitored, instead undergo treatmentacross the UK, an average of 8% of men who could be monitored are treated instead, amounting to 5,000 a yearSome of this could be down to patient choice – men are generally given the option of treatment even if they are at the charity said if the NHS was more active in offering monitoring it could help strengthen the case for prostate cancer screening, which has gained traction since the diagnosis of Olympic cyclist Sir Chris argument against screening is that the prostate specific antigen (PSA) blood test, used to spot potential signs of the cancer, is unreliable and leads to unnecessary Rylance of Prostate Cancer UK, said: "To reduce the harm caused by prostate cancer and build the foundations for a screening programme, we need to both save lives and prevent unnecessary treatment."One patient who opted for monitoring was Michael Lewis, 63, from the West was diagnosed with prostate cancer in 2020 and, as it was judged low-risk, he opted for monitoring. Four years later tests suggested the cancer was worsening so he had his prostate removed. He said delaying treatment was so valuable."I was able to continue my everyday life with no side effects."NICE said the organisation was reviewing the prostate cancer guidelines and looking to update them."We are committed to ensuring our guidelines continue to reflect the best available evidence and give patients the best possible outcomes," said a spokesman.